Clinical trial results:
Coagulopathy during surgery for the repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - feasibility study of the use of Fibrinogen Concentrate by infusion in place of Fresh Frozen Plasma.

Summary

EudraCT number	2009-016709-41
Trial protocol	GB
Global end of trial date	31 December 2014

Results information

Result version number	v1 (current)
This version publication date	19 August 2021
First version publication date	19 August 2021
Summary attachment (see zip file)	Journal (Morrison_et_al-2019-Anaesthesia.pdf)

Trial information

Trial identification

Sponsor protocol code	FIB692

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00994045
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ACCORD (University of Edinburgh and NHS Lothian)
Sponsor organisation address	47 Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
Public contact	Dr Alastair Nimmo, NHS Lothian, +44 0131 242 3224, a.nimmo@ed.ac.uk
Scientific contact	Dr Alastair Nimmo, NHS Lothian, +44 0131 242 3224, a.nimmo@ed.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 July 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 August 2013
Global end of trial reached?	Yes
Global end of trial date	31 December 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the pattern of coagulation abnormalities in both groups (fibrinogen group and Fresh Frozen Plasma group).

Protection of trial subjects:

This single-centre study was approved by a research ethics committee, and clinical trial authorisation was granted by the Medicines and Healthcare products Regulatory Agency (MHRA). Written informed consent was obtained from all participants.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 June 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3
From 65 to 84 years	17
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Between June 2010 and August 2013, twenty-three patients were assessed for enrolment in the study of whom 20 completed the study (10 in each group). Three patients were excluded: taking warfarin (n = 1); declined to participate (n = 1); research staff unavailable (n = 1).

Pre-assignment

Screening details:

This was a small, single site pilot study. The study did not require the collection of information about patients screened for eligibility.

Period 1

Period 1 title	Baseline (overall trial) (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Fresh frozen plasma (FFP)

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Fresh Frozen Plasma (FFP)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The FFP group received FFP at an initial rate of 15 ml.kg-1.h-1 (approximately 40 mg.kg-1.h-1 of fibrinogen).

Arm title	Fibrinogen concentrate

Arm description:

Fibrinogen concentrate is derived from pooled human plasma which is purified, treated to inactivate pathogens and freeze dried. It may be stored at room temperature in the operating room and then dissolved in sterile water when required.

Arm type	Active comparator
Investigational medicinal product name	Fibrinogen concentrate
Investigational medicinal product code	BT524
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Fibrinogen concentrate at 40 mg.kg-1.h-1. Infusion rates were doubled, left unchanged or halved according to subsequent FIBTEM results. The infusions were stopped if FIBTEM A10 was ≥ 8 mm and there was no significant ongoing bleeding.

Number of subjects in period 1	Fresh frozen plasma (FFP)	Fibrinogen concentrate
Started	10	10
Completed	10	10

Baseline characteristics

Reporting groups	
Reporting group title	Baseline (overall trial)

Reporting group description: -

Reporting group values	Baseline (overall trial)	Total	
Number of subjects	20	20	
Age categorical Units: Subjects			
Adults (18-64 years)	3	3	
From 65-84 years	17	17	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	6	6	
Male	14	14	

End points

End points reporting groups

Reporting group title	Fresh frozen plasma (FFP)
Reporting group description: -	
Reporting group title	Fibrinogen concentrate
Reporting group description:	
Fibrinogen concentrate is derived from pooled human plasma which is purified, treated to inactivate pathogens and freeze dried. It may be stored at room temperature in the operating room and then dissolved in sterile water when required.	

Primary: Allogeneic blood components

End point title	Allogeneic blood components
End point description:	
End point type	Primary
End point timeframe:	
During surgery and up to 24 h postoperatively.	

End point values	Fresh frozen plasma (FFP)	Fibrinogen concentrate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	10		
Units: ml				
median (inter-quartile range (Q1-Q3))	22.5 (2 to 41)	4.5 (0 to 17)		

Statistical analyses

Statistical analysis title	Allogeneic blood components
Comparison groups	Fibrinogen concentrate v Fresh frozen plasma (FFP)
Number of subjects included in analysis	20
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.011
Method	Wilcoxon (Mann-Whitney)

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events: Randomisation to 24 hours post surgery.	
Assessment type	Systematic

Dictionary used	
Dictionary name	Not applicable
Dictionary version	0

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: There were no adverse events including non-serious adverse events.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 March 2010	Increase in volume of blood taken from each patient to allow all the necessary clotting tests to be performed. Blood taken at each sampling point will increase from 15mls to 22.5mls and max total will increase from 180mls to 270 mls. Modification of pharmacy label that will be applied to study drug. Drug label now states that drug must be stored at below 25 degrees & do not freeze.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/30467829